Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mediford Corporation operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This action is assigned to 1 distinct examiner, HOLLAND, PAUL J, who is working in 1 distinct art unit. The data shows that HOLLAND, PAUL J is the busiest examiner with 1 busiest examiner pending. This concentration means that the company's immediate patent outcomes are determined by this 1 distinct examiner. The involvement of 1 distinct art unit suggests a focused technical scope.
For a portfolio with 1 pending office action, the prosecution strategy is highly centralized. Practitioners should prioritize understanding the specific examination patterns of the 1 distinct examiner assigned to the case. The lack of examiner diversity means there is no internal baseline for comparing examiner behavior within this portfolio. Consequently, the immediate success of the company's patent strategy depends on the interactions with HOLLAND, PAUL J. Every response to the 1 pending office action must be carefully tailored to the specific requirements of the 1 distinct art unit. This concentration means that the company's immediate patent prospects are shaped by a single individual's interpretation.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLAND, PAUL J | 1 | 57.3% | +64.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17905009 | METHOD FOR ANALYZING NUCLEIC ACID DRUGS | HOLLAND, PAUL J | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17905009 | METHOD FOR ANALYZING NUCLEIC ACID DRUGS | HOLLAND, PAUL J | 1656 | §103 | Non-Final OA | — | Pending | Aug 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMediford Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul J Holland has the most, with 1 of Mediford Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
